8-K: AirSculpt Reports Q2 2026 Results: Stable Cases, Lower Revenue

AirSculpt Technologies announced second quarter fiscal 2026 results, showing stable same-center case volume but a decline in revenue and Adjusted EBITDA compared to the prior year.

Summary

• AirSculpt Technologies reported its second quarter fiscal 2026 results for the period ending June 30, 2026.
• The company achieved stable same-center case volume, growing 1.0% in Q2 2026 and 1.1% year-to-date compared to the prior year.
• However, revenue for the quarter decreased by 3% to $42.9 million from $44.0 million in Q2 2025.
• Net loss for the quarter was $1.1 million, an increase from a $0.6 million net loss in the prior year's second quarter.
• Adjusted EBITDA for Q2 2026 was $4.9 million, down from $5.8 million in Q2 2025.
• The company is reaffirming its full-year 2026 revenue guidance at the lower end of $151-$157 million but is reducing its Adjusted EBITDA outlook to $12-$14 million.
• AirSculpt has reduced its gross debt by approximately $30 million since the start of 2025, bringing it to $44.2 million as of June 30, 2026.
• Cash and cash equivalents increased to $18.8 million as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a slightly negative score due to declining revenue and Adjusted EBITDA, despite efforts to stabilize case volume and expand service offerings.

Positives

• Same-center case volume grew 1.0% in Q2 2026 and 1.1% year-to-date, indicating stability in core operations.
• The company has reduced its gross debt by approximately $30 million since the start of 2025, now standing at $44.2 million.
• Cash and cash equivalents increased to $18.8 million as of June 30, 2026, up from $8.4 million at the end of 2025.
• Introduced new services, including a partnership with AlloClae, to broaden the service offering and addressable patient population.
• Invested in marketing to increase brand awareness.
• Entered into an amended term loan agreement extending its maturity to November 2027.

Negatives

• Revenue declined 3% to $42.9 million in Q2 2026 compared to $44.0 million in Q2 2025.
• Net loss for Q2 2026 was $1.1 million, an increase from $0.6 million in Q2 2025.
• Adjusted EBITDA decreased to $4.9 million in Q2 2026 from $5.8 million in Q2 2025.
• Full-year Adjusted EBITDA outlook was reduced to $12-$14 million.
• Case volume decreased slightly by 0.5% in Q2 2026 compared to the prior year's second quarter.
• Revenue per case saw a slight decrease in Q2 2026 compared to Q2 2025.

Risks

• Increased competition in the weight loss and obesity solutions market, including due to weight-loss drugs.
• Potential inability to raise capital on commercially reasonable terms or dilution from future financings.
• Failure to stabilize same-store performance or optimize marketing investment and go-to-market strategy.
• Inability to expand financing options for consumers.
• Unsuccessful product innovations or failure to operate centers cost-effectively.
• Increased operating expenses due to rising inflation.
• Shortages or quality control issues with third-party manufacturers or suppliers.
• Litigation or medical malpractice claims.

Future Outlook

The company is reaffirming its full-year 2026 revenue guidance at the lower end of its range ($151-$157 million) but is reducing its Adjusted EBITDA outlook to $12-$14 million.

Management Comments

• "In the second quarter, we advanced our key priorities delivering our second quarter of stability."
• "During the quarter, we stepped up our investment in marketing and advanced our plans to introduce new, sought-after procedures including entering an exclusive partnership with AlloClae that expands our treatment offering and enhances our body contouring platform."
• "We enter the second half of the year a fundamentally stronger company with the right strategy and team. Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was twelve months ago."

Industry Context

StockSavvy.ai notes that the body contouring market is increasingly competitive, with emerging trends like weight-loss drugs potentially impacting demand for traditional procedures. AirSculpt's strategy to broaden its service offering and invest in marketing aims to counter these pressures.

Comparison to Industry Standards

• The filing does not provide direct comparisons to specific industry benchmarks or competitors' financial results.
• However, the mention of increased competition from weight-loss drugs suggests a dynamic market where traditional body contouring may face evolving consumer preferences.

Legal Proceedings

• The filing mentions 'Litigation settlements' as an add-back for Adjusted EBITDA, indicating past or ongoing legal matters, but provides no specific details.

Stakeholder Impact

• Shareholders may be concerned by the decline in revenue and Adjusted EBITDA, as well as the reduced full-year EBITDA outlook.
• Creditors may see the debt reduction and amended loan terms as positive steps towards financial stability.

Next Steps

• Continue to invest in marketing and brand awareness.
• Introduce new procedures and expand treatment offerings.
• Make an additional $2.5 million term loan payment on or before September 30, 2026.
• Apply 50% of net proceeds from future equity issuances to prepay term loans.

Key Dates

Recommendation

The company shows signs of operational stability with consistent case volumes and debt reduction efforts. However, declining revenue, increased net loss, and a reduced Adjusted EBITDA outlook suggest caution. The stock is best held while the company demonstrates a clear path to revenue growth and improved profitability amidst competitive pressures.

Keywords

body contouring, plastic surgery, cosmetic procedures, fat removal, revenue, Adjusted EBITDA, financial results, AlloClae